H.C. Wainwright Reaffirms Their Buy Rating on Immunomedics (IMMU)

By Austin Angelo

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Immunomedics (IMMUResearch Report) today and set a price target of $26.00. The company’s shares closed last Monday at $18.75.

According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.6% and a 40.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Immunomedics has an analyst consensus of Strong Buy, with a price target consensus of $26.20.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.13 and a one-year low of $11.55. Currently, Immunomedics has an average volume of 2.13M.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMMU in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments.